Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site‐ and Sequence‐Specific Drug Release

Time-staggered combination chemotherapy strategies show immense potential in cell culture systems, but fail to successfully translate clinically due to different routes of administration and disparate formulation parameters that preclude a specific order of drug presentation. A novel platform consisting of drug-containing PLGA polymer nanoparticles, stably fashioned with a shell composed of drug complexed with cationic cyclodextrin, capable of releasing drugs time- and sequence-specifically within tumors is designed. Morphological examination of nanoparticles measuring 150 nm highlight stable and distinct compartmentalization of model drugs, rhodamine and bodipy, within the core and shell, respectively. Sequential release is observed in vitro, owing to cyclodextrin shell displacement and subsequent sustained release of core-loaded drug, kinetics preserved in breast cancer cells following internalization. Importantly, time-staggered release is corroborated in a murine breast cancer model following intravenous administration. Precise control of drug release order, site-specifically, potentially opens novel avenues in polychemotherapy for synergy and chemosensitization strategies.

[1]  Michael B. Yaffe,et al.  Cytokine-Induced Signaling Networks Prioritize Dynamic Range over Signal Strength , 2008, Cell.

[2]  M. Ferrari,et al.  Intracellular trafficking of silicon particles and logic-embedded vectors. , 2010, Nanoscale.

[3]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[4]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[5]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[6]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Russell J Mumper,et al.  Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. , 2009, Cancer research.

[8]  W. Gradishar,et al.  Albumin-bound paclitaxel: a next-generation taxane , 2006, Expert opinion on pharmacotherapy.

[9]  L Biganzoli,et al.  EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  H. Temple,et al.  mTORC1 inhibition and ECM–cell adhesion-independent drug resistance via PI3K–AKT and PI3K–RAS–MAPK feedback loops , 2012, Tumor Biology.

[11]  X. Jing,et al.  Biodegradable copolymers with identical cationic segments and their performance in siRNA delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[13]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.

[14]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[15]  W. Mark Saltzman,et al.  Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA , 2009, Nature materials.

[16]  David Miles,et al.  Combination versus sequential single-agent therapy in metastatic breast cancer. , 2002, The oncologist.

[17]  Mark E. Davis,et al.  Cyclodextrin-based pharmaceutics: past, present and future , 2004, Nature Reviews Drug Discovery.

[18]  V. Labhasetwar,et al.  Biodegradable nanoparticles for cytosolic delivery of therapeutics. , 2007, Advanced drug delivery reviews.

[19]  Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[20]  E. Vega,et al.  Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. , 2009, Colloids and surfaces. B, Biointerfaces.

[21]  Youqing Shen,et al.  Challenges in design of translational nanocarriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Zhongdang Xiao,et al.  Modification of silicon AFM cantilever tips with an oligo(ethylene glycol) derivative for resisting proteins and maintaining a small tip size for high-resolution imaging. , 2003, Journal of the American Chemical Society.

[23]  N. McCarthy.  Cell death: 1+1≠2 , 2012, Nature Reviews Cancer.

[24]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[25]  Ho-Chul Shin,et al.  Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG , 2012, Molecular Cancer Therapeutics.

[26]  Thorsteinn Loftsson,et al.  Cyclodextrins as functional excipients: methods to enhance complexation efficiency. , 2012, Journal of pharmaceutical sciences.

[27]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[28]  Lin Mei,et al.  The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment. , 2014, Biomaterials.

[29]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[30]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[31]  G. Mills,et al.  Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[32]  Guangjun Nie,et al.  Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. , 2011, Biomaterials.

[33]  J. Kolitz,et al.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Gendron,et al.  Diffusion Coefficients of Several Rhodamine Derivatives as Determined by Pulsed Field Gradient–Nuclear Magnetic Resonance and Fluorescence Correlation Spectroscopy , 2008, Journal of Fluorescence.

[35]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[36]  S. Howorka,et al.  Nanomechanical recognition measurements of individual DNA molecules reveal epigenetic methylation patterns. , 2010, Nature nanotechnology.

[37]  R. Athawale,et al.  Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles , 2014, DARU Journal of Pharmaceutical Sciences.

[38]  P. Decuzzi,et al.  siRNA-chitosan complexes in poly(lactic-co-glycolic acid) nanoparticles for the silencing of aquaporin-1 in cancer cells. , 2013, Molecular pharmaceutics.